High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana university experience

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1096-1102

  Adra, Nabil ^a   Abonour, Rafat ^a   Althouse, Sandra K ^a   Albany, Costantine ^a   Hanna, Nasser H ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CIPROFLOXACIN; CISPLATIN; ETOPOSIDE; FLUCONAZOLE; VANCOMYCIN; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; FOLLOW UP; GERM CELL TUMOR; HIGH DOSE CHEMOTHERAPY; HISTOPATHOLOGY; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OTOTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEMINOMA; VOMITING; AUTOTRANSPLANTATION; BLOOD; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETREATMENT; RETROPERITONEAL NEOPLASMS; RISK FACTOR; SECONDARY; SURVIVAL RATE; TESTICULAR NEOPLASMS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHORIONIC GONADOTROPIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; LEUKEMIA; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETREATMENT; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 85016604723     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.5395     Document Type: Article

References (23)

1. Nigam M, Aschebrook-Kilfoy B, Shikanov S, et al: Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 33:623-631, 2015
2. Hanna NH, Einhorn LH: Testicular cancer-Discoveries and updates. N Engl J Med 371: 2005-2016, 2014
3. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603, 1997
4. Adra N, Ku K, Kalra M, et al: Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: The Indiana University (IU) experience. J Clin Oncol 34, 2016 (suppl 2S; abstr 491)
5. Murphy BR, Breeden ES, Donohue JP, et al: Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11:324-329, 1993
6. Loehrer PJ, Sr, Einhorn LH, Williams SD: VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4:528-536, 1986
7. Loehrer PJ Sr, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998
8. Kondagunta GV, Bacik J, Donadio A, et al: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23: 6549-6555, 2005
9. Nichols CR, Tricot G, Williams SD, et al: Doseintensive chemotherapy in refractory germ cell cancer-A phase I/II trial of high-dose carboplatin and etoposidewith autologous bonemarrow transplantation. J Clin Oncol 7:932-939, 1989
10. Einhorn LH, Williams SD, Chamness A, et al: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357: 340-348, 2007
11. Feldman DR, Sheinfeld J, Bajorin DF, et al: TI-CE high-dose chemotherapy for patients with previously treated germcell tumors: Results and prognostic factor analysis. J Clin Oncol 28:1706-1713, 2010
12. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer. JAMA 299:672-684, 2008
13. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351, 2000
14. Cooper MA, Einhorn LH: Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167-1169, 1995
15. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36-39, 1990 (1, suppl 2)
16. Ko JJ, Bernard B, Tran B, et al: Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. J Clin Oncol 34:714-720, 2016
17. Lorch A, Bascoul-Mollevi C, Kramar A, et al: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database. J Clin Oncol 29:2178-2184, 2011
18. Beyer J, Kramar A, Mandanas R, et al: Highdose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645, 1996
19. International Prognostic Factors Study Group: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28:4906-4911, 2010
20. Lorch A, Kleinhans A, Kramar A, et al: Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: Long-term results of a prospective randomized trial. J Clin Oncol 30:800-805, 2012
21. Pico JL, Rosti G, Kramar A, et al: A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16:1152-1159, 2005
22. Collette L, Sylvester RJ, Stenning SP, et al: Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. J Natl Cancer Inst 91:839-846, 1999
23. Stiller CA: Non-specialist units, clinical trials and survival from testicular cancer. Eur J Cancer 31A: 289-291, 1995